Cardioprotection by Sevoflurane Preconditioning in Noncardiac Thoracic Surgery

Helio's Health

Status: Completed

Conditions: High Sensitive Troponin T Release

Treatments: Drug: Sevoflurane; Drug: TIVA

Study type: Interventional

Funder types: Industry

Identifiers

NCT02217319

HSK005

Details and patient eligibility

About

It has been shown that the use of volatile anaesthetics, that are usually used to perform a general anesthesia, have cardioprotective properties. This has been shown in animal studies and in patients that underwent cardiac surgery. The aim of our study is to examine if Sevoflurane, a volatile anaesthetic, has this properties in patients undergoing lung surgery.

Enrollment: 100 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Lung surgery
• ASA (American Society of Anesthesiologists) physical status 1-3

Exclusion criteria

• Disposition for malignant hyperthermia
• Medication with ß-blocking drugs
• Use of clonidin

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

100 participants in 2 patient groups, including a placebo group

Sevoflurane

Active Comparator group

Description:

Patients receive Sevoflurane 1 MAC (minimal alveolar concentration) after induction of anesthesia with propofol, remifentanil and atracurium for 30 minutes as preconditioning.

Treatment:

Drug: Sevoflurane

TIVA

Placebo Comparator group

Description:

Patients received the standard total intravenous anesthesia (TIVA) with propofol, remifentanil and atracurium.

Treatment:

Drug: TIVA